Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report

Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies including non-small-cell lung cancer (NSCLC). Immune-mediated colitis is a known adverse effect of pembrolizumab which can lead to the treatment interruption, althou...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Oncol
Prif Awduron: Damato, Angela, De Marco, Loredana, Serra, Silvia, Larocca, Mario, Arias, Alicia Garcia, Rondini, Ermanno, Pinto, Carmine
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2021
Pynciau:
Oncology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8248363/
https://ncbi.nlm.nih.gov/pubmed/34221986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.670415
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg